A Double-blind, Randomized, Cross-over Study to Compare the Impact of Rapid-acting Insulin Aspart and Faster Acting Aspart (FiAsp) on Glucose Excursion During Postprandial Exercise in Adults With Type 1 Diabetes
Phase of Trial: Phase IV
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 03 Jun 2019 Status changed from not yet recruiting to recruiting.
- 29 Jan 2019 Planned End Date changed from 1 Oct 2020 to 1 Feb 2021.
- 29 Jan 2019 Planned primary completion date changed from 1 Oct 2020 to 1 Feb 2021.